INTRODUCTION
Liver transplantation is the treatment of choice for various causes of end-stage liver disease in children1. Remarkable progress has been made in the field since the first human orthotopic liver transplant was performed in a child in 19632. The This overview of the field will attempt to highlight aspects of liver transplantation especially pertinent to pediatrics including childhood diseases, technical considerations in children, and technical complications.
DISEASES TRANSPLANTED
The diseases in pediatric patients treated with OLT at UCLA are listed in Table 1 . Biliary atresia was the most common followed by inborn errors of metabolism, and "cirrhosis" from various causes. This is consistent with reports from other institutions with large pediatric OLT programs3.
BILIARY ATRESIA This is the most common indication for liver transplantation in children as noted above. Biliary atresia can be defined as a partial or complete absence of patent bile ducts. The incidence varies from 1:8,000 to 1"10,000 with a 4-5 fold increase in In conclusion, children with biliary atresia should undergo early portoenterostomy, but at the first Sign of failure should be referred for OLT evaluation.
INBORN ERRORS OF METABOLISM

Alpha-l-antitrypsin deficiency
This is the most common of the metabolic disorders for which OLT is performed.
Cirrhosis associated with ATT deficiency was first reported in 10 children in 196915.
Alpha-l-antitrypsin is one of several serine proteases synthesized in the liver which inhibit a wide variety of proteolytic enzymes within plasma, including trypsin16. The This has permitted significantly longer preservation times without compromise of graft function. It is felt that the ability to lengthen preservation times will help change the nature of liver transplantation practice as it permits greater flexibility in utilization of operating room time and resources. Also the timing of donor and recipient operation is not as critical, and this permits improved utilization of available donor organs.
COMPLICATIONS
The complications of orthotopic liver transplantation to be discussed are outlined on Table 2 . They have been somewhat arbitrarily divided into "hepatic" and "nonhepatic". 
PSEUDOANEURYSMS
This is an extremely rare complication of OLT. In a report of eleven pseudoaneurysms, five were nonanastomotic with three of these being related to infection. They were mostly found incidentally on imaging studies, though they may present with rupture, hemobilia or as an enteric fistula. Operative correction is needed because of the high risk of significant complications62.
VENOUS COMPLICATIONS
The incidence of portal vein or inferior vena cava thrombosis is much lower than that of arterial thrombosis with rates less than 2% reported63. We have had no cases of venous thrombosis at UCLA. The 
BILIARY COMPLICATIONS
Biliary complications used to be the most common and lethal complication following orthotopic liver transplantation, and was considered the "achilles heel" of liver transplantation66. With increasing experience and standardization of reconstructions, results have improved significantly. Recent series report biliary tract complications in pediatric patients at 7-20% 56,67. In adults, biliary leakage is the most common complication, and the most common site is at the T-tube exit site68. In children, use of T-tubes are rare and leakage is commonly from the choledochojejunostomy. Presentation is that of fever, abdominal pain, elevated bilirubin and hepatic enzymes, and increased drain output. Diagnosis can be confirmed by transhepatic cholangiogram or ERCP if necessary. Treatment is antibiotic coverage and either simple surgical repair or revision of the anastomosis. Contributing factors to biliary leaks are technical errors at the anastomosis, ischemia from using a too long segment of donor duct, 6 and hepatic artery thrombosis. In our pediatric patients, eight developed biliary leaks, of which five required simple closure and three needed revision of the anastomosis.
Obstruction is the other major biliary complication. The The first CsA dose is given pre-operatively at 15mg/kg orally. The post-operative doses are started after adequate urine output is established at 3-5mg/kg/day intravenously in two divided doses. Each dose is infused over four hours. The dose is adjusted daily based on CsA trough plasma levels with a target range of 200-300ng/ml. After oral intake is established, oral CsA is started at 10-15mg/kg/day in two divided doses. The intravenous dose is continued and tapered as therapeutic levels are reached with the oral dose. The overlap is usually 5-7 days. In cases of renal insufficiency, CsA doses are decreased accordingly or even held as indicated.
Azathioprine is started at 1-2mg/kg/day intravenously on the first post-transplant day and later converted to the same oral dose. It is held in cases of neutropenia or severe sepsis.
MAINTENANCE IMMUNOSUPPRESSION
Again, triple-drug therapy is used in most patients. Prednisone is tapered gradually and maintained on as low a dose as possible. Cyclosporine doses are adjusted so that higher levels are maintained early after OLT but allowed to drop to the 140-160ng/ml range in stable patients greater than one year after OLT. In patients with stable levels and renal function, levels are checked about every two months. Azathioprine is maintained at lmg/kg/day. 
